Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in Costa Rica.

Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE

Publication: Jan. 2011- : Oxford : Oxford University Press
Original Publication: 1904-2010 : Chicago, IL : University of Chicago Press

Anus Neoplasms/*epidemiology ; Papillomavirus Infections/*epidemiology; Adult ; Anus Neoplasms/virology ; Costa Rica/epidemiology ; Female ; Human papillomavirus 16/genetics ; Human papillomavirus 18/genetics ; Humans ; Logistic Models ; Multivariate Analysis ; Papillomavirus Infections/virology ; Prevalence ; Randomized Controlled Trials as Topic ; Risk Factors ; Young Adult

Background: Anal cancer is caused by human papillomavirus (HPV), yet little is known about anal HPV infection among healthy young women.
Methods: A total of 2017 sexually active women in the control arm of an HPV-16/18 vaccine trial had a single anal specimen collected by a clinician at the 4-year study visit. Samples were tested for HPV by SPF(10) PCR/DEIA/LiPA(25), version 1.
Results: A total of 4% of women had HPV-16, 22% had oncogenic HPV, and 31% had any HPV detected in an anal specimen. The prevalence of anal HPV was higher among women who reported anal intercourse, compared with those who did not (43.4% vs 28.4%; P< .001). Among women who reported anal intercourse, cervical HPV (adjusted odds ratio [aOR], 5.3 [95% confidence interval {CI}, 3.4-8.2]), number of sex partners (aOR, 2.2 [95% CI, 1.1-4.6] for ≥ 4 partners), and number of anal intercourse partners (aOR, 1.9 [95% CI, 1.1-3.3] for ≥ 2 partners) were independent risk factors for anal HPV detection. Among women who reported no anal intercourse, cervical HPV (aOR, 4.7 [95% CI, 3.7-5.9]), number of sex partners (aOR, 2.4 [95% CI, 1.7-3.4] for ≥ 4 partners), and report of anal fissures (aOR, 2.3 [95% CI, 1.1-4.8]) were associated with an increased odds of anal HPV detection.
Conclusion: Anal HPV is common among young women, even those who report no anal sex, and was associated with cervical HPV infection. Anal fissures in women who report never having had anal intercourse may facilitate HPV exposure.
Clinical Trials Registration: NCT00128661.

Sex Health. 2010 Sep;7(3):244-52. (PMID: 20719211)
J Infect Dis. 2001 Feb 1;183(3):383-91. (PMID: 11133369)
Cancer. 2004 Jul 15;101(2):270-80. (PMID: 15241823)
Int J Cancer. 2009 May 15;124(10):2375-83. (PMID: 19189402)
Int J Cancer. 2009 Apr 1;124(7):1626-36. (PMID: 19115209)
J Infect Dis. 1998 Feb;177(2):361-7. (PMID: 9466522)
Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2550-6. (PMID: 16284377)
J Clin Microbiol. 1996 Mar;34(3):745-7. (PMID: 8904451)
Dis Colon Rectum. 2001 May;44(5):690-8. (PMID: 11357031)
Lancet Oncol. 2011 Sep;12(9):862-70. (PMID: 21865087)
J Infect Dis. 2010 May 15;201(10):1498-508. (PMID: 20367457)
Vaccine. 2008 Sep 2;26(37):4795-808. (PMID: 18640170)
Clin Infect Dis. 2009 Mar 1;48(5):536-46. (PMID: 19191636)
Gynecol Oncol. 2009 Sep;114(3):399-403. (PMID: 19501896)
J Clin Microbiol. 2006 Sep;44(9):3292-8. (PMID: 16954263)
Br J Cancer. 2009 Feb 10;100(3):527-31. (PMID: 19156144)
Cancer. 2004 Jul 15;101(2):281-8. (PMID: 15241824)
N Engl J Med. 1997 Nov 6;337(19):1350-8. (PMID: 9358129)
AIDS. 1994 Mar;8(3):283-95. (PMID: 8031509)
Obstet Gynecol. 1994 Feb;83(2):205-11. (PMID: 8290181)
Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25. (PMID: 16949997)
BMJ. 1993 Feb 13;306(6875):419-22. (PMID: 8461721)
J Clin Microbiol. 1999 Aug;37(8):2508-17. (PMID: 10405393)
Int J Cancer. 2011 Jul 15;129(2):433-9. (PMID: 20839262)
Am J Pathol. 1998 Dec;153(6):1731-9. (PMID: 9846964)

N01CP11005 United States CP NCI NIH HHS

Investigator: M Alfaro; M Barrantes; M Bratti; F Cárdenas; B Cortés; A Espinoza; Y Estrada; P González; D Guillén; R Herrero; SE Jiménez; J Morales; L Villegas; LA Morera; E Pérez; C Porras; AC Rodríguez; L Rivas; E Freer; J Bonilla; A García-Piñeres; S Silva; I Atmella; M Ramírez; A Hildesheim; AR Kreimer; DR Lowy; N Macklin; M Schiffman; JT Schiller; M Sherman; D Solomon; S Wacholder; L Pinto; T Kemp; C Eklund; M Hutchinson; M Sidawy; W Quint; LJ van Doorn; L Struijk; B Blanco; R Cerdas; A Hernández; JM González; O López; M Sánchez; R Thompson; J Umaña; SY Araya; H Barquero; H Campos; M Grijalba; AC Monge; A Peraza; D Robles; F Sáenz; D Vargas; J Vindas; P Alvarez; D Angulo; AL Arias; B Barrantes; M Bonilla; M José Calvo; L Carvajal; J Chinchilla; B Cruz; M Herrera; A Interiano; F Jiménez; E Lagos; V Loría; A Messeguer; R Ocampo; S Padilla; A Ramírez; L Rivas; D Romero; B Romero; J Ruiz; D Ruiz; G Saborío; S Ssoto; M Salas; A Torrez; N Ugalde; AC Ugalde; A Vallejos; Y Vázquez; M Villegas; M Alvarado; AC Arroyo; G Barrientos; D Díaz; M Jara; M Matarrita; ME Molina; E Ordóñez; G Sánchez; Z Villegas; A Castrillo; V López; K Coronado; R Alfaro; C Sánchez; L Romero; C Montero; C Avila; E Alpízar; S Elizondo; J Cyr; J Buckland; L Rich; D Buckman; KG Morrisey; K Midkiff; S Truitt; S Stoszek; M Gomez; I Trejos; C Chorley; T Moore; K Shea; H Siefers; G Dubin; A Schuind; F Struyf; K Lawrence; D Fu; B Innis; F Dessy; C Bougelet; S Self; A Benavides; LD Calzada; R Karron; R Nayar; N Roach; J Cain; D Davey; D DeMets; F Fuster; A Gershon; E Holly; S Lara; H Raventós; W Rida; L Rosero-Bixby; K Suthers; S Thomas; R Viscidi; A Westbroek; Y Zomerdijk; J Schussler; N Macklin; MT Goodman; B Hernandez; Y Shvetsov

ClinicalTrials.gov NCT00128661

Date Created: 20120802 Date Completed: 20121123 Latest Revision: 20220316

20250114

PMC3499109

10.1093/infdis/jis458

22850119